Maurizio Degiuli

Dr. Maurizio Degiuli

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2013 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
TGthe Italian Gastric Cancer Study Group
the Italian Gastric Cancer Study Group
MDMaurizio Degiuli
Maurizio Degiuli
MSM. Sasako
M. Sasako
APA. Ponti
A. Ponti
AVA. Vendrame
A. Vendrame
PTP Mello Teggia
P Mello Teggia

23 February 2010 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MDMaurizio Degiuli
Maurizio Degiuli
MSM. Sasako
M. Sasako
APA. Ponti
A. Ponti

1 April 2004 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MDMaurizio Degiuli
Maurizio Degiuli
MSM Sasako
M Sasako
MCM Calgaro
M Calgaro
MGM Garino
M Garino
FRF Rebecchi
F Rebecchi
FCF Calvo
F Calvo

2 June 2016 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
GMGiovanni De Manzoni
Giovanni De Manzoni
Daniele MarrelliDaniele Marrelli
Daniele Marrelli
GBGian Luca Baiocchi
Gian Luca Baiocchi
PMPaolo Morgagni
Paolo Morgagni
LSLuca Saragoni
Luca Saragoni
FRFranco Roviello
Franco Roviello

24 November 2021 in Colorectal Disease
Verified
Journal Article
Open access
PDF file
MDMaurizio Degiuli
Maurizio Degiuli
UEUgo Elmore
Ugo Elmore
RLRAFFAELE DE LUCA
RAFFAELE DE LUCA
PNPaola De Nardi
Paola De Nardi
MTMariano Tomatis
Mariano Tomatis
TGThe Italian Society of Surgical Oncology – Colorectal Cancer Network Collaborative Group
The Italian Society of Surgical Oncology – Colorectal Cancer Network Collaborative Group
Aim: Anastomotic leakage after restorative surgery for rectal cancer shows high morbidity and related mortality. Identification of risk factors could change operative planning, with indications for stoma construction. This retrospective multicentre study aims to assess the anastomotic leak rate, identify the independent risk factors and develop a clinical prediction model to calculate the probability of leakage.Methods: The study used data from 24 Italian referral centres of the Colorectal Cancer Network of the Italian Society of Surgical Oncology. Patients were classified into two groups, AL (anastomotic leak) or NoAL (no anastomotic leak). The effect of patient‐, disease‐, treatment‐ and postoperative outcome‐related factors on anastomotic leak after univariable and multivariable analysis was measured.Results: A total of 5398 patients were included, 552 in group AL and 4846 in group NoAL. The overall incidence of leaks was 10.2%, with a mean time interval of 6.8 days. The 30‐day leak‐related mortality was 2.6%. Sex, body mass index, tumour location, type of approach, number of cartridges employed, weight loss, clinical T stage and combined multiorgan resection were identified as independent risk factors. The stoma did not reduce the leak rate but significantly decreased leak severity and reoperation rate. A nomogram with a risk score (RALAR score) was developed to predict anastomotic leak risk at the end of resection.Conclusions: While a defunctioning stoma did not affect the leak risk, it significantly reduced its severity. Surgeons should recognize independent risk factors for leaks at the end of rectal resection and could calculate a risk score to select high‐risk patients eligible for protective stoma construction.

6 April 2004 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MDMaurizio Degiuli
Maurizio Degiuli
MSM Sasako
M Sasako
APA Ponti
A Ponti
FCF Calvo
F Calvo
Curative resection is the treatment of choice for potentially curable gastric cancer. Two major Western studies in the 1990s failed to show a benefit from D2 dissection. They showed extremely high postoperative mortality after D2 dissection, and were criticised for the potential inadequacy of the pretrial training in the new technique of D2 dissection, prior to the phase III studies being initiated. The inclusion of pancreatectomy and splenectomy in D2 dissection was associated with increased morbidity and mortality. Following these results, we started a phase II trial to evaluate the safety and efficacy of pancreas-preserving D2 dissection. The results of this trial regarding the safety of pancreas preserving D2 dissection were published in 1998. In this paper, we present the survival results of this phase II trial to confirm the rationale of carrying out a phase III study comparing D1 vs D2 dissection for curable gastric cancer. Italian patients with histologically proven gastric adenocarcinoma were registered in the Italian Gastric Cancer Study Group Multicenter trial. The study was carried out based on the General Rules of the Japanese Research Society for Gastric Cancer. A strict quality control system was achieved by a supervising surgeon of the reference centre who had stayed at the National Cancer Center Hospital, Tokyo, to learn the standard D2 gastrectomy and the postoperative management. The standard procedure entailed removal of the first and second tier lymph nodes. During total gastrectomy, the pancreas was preserved according to the Maruyama technique. Complete follow-up was available to death or 5 years in 100% of patients and the median follow-up time was 4.38 years. Out of 297 consecutive patients registered, 191 patients were enrolled in the study between May 1994 and December 1996. The overall morbidity rate was 20.9%. The postoperative in-hospital mortality was 3.1%. The overall 5-year survival rate among all eligible patients was 55%. Survival was strictly related to stage, depth of wall invasion, lymph node involvement and type of gastrectomy (distal vs total). Our results suggest a survival benefit for pancreas-preserving D2 dissection in Italian patients with gastric cancer if performed in experienced centres. A phase III trial among exclusively experienced centres is urgently needed.